These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 29222833)

  • 21. Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials.
    Marcello M; Denham JW; Kennedy A; Haworth A; Steigler A; Greer PB; Holloway LC; Dowling JA; Jameson MG; Roach D; Joseph DJ; Gulliford SL; Dearnaley DP; Sydes MR; Hall E; Ebert MA
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1304-1318. PubMed ID: 32739320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of treatment planning and delivery factors on gastrointestinal toxicity: an analysis of data from the RADAR prostate radiotherapy trial.
    Yahya N; Ebert MA; Bulsara M; Haworth A; Kearvell R; Foo K; Kennedy A; Richardson S; Krawiec M; Joseph DJ; Denham JW
    Radiat Oncol; 2014 Dec; 9():282. PubMed ID: 25498565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
    Zapatero A; Guerrero A; Maldonado X; Alvarez A; Gonzalez San Segundo C; Cabeza Rodríguez MA; Macias V; Pedro Olive A; Casas F; Boladeras A; de Vidales CM; Vazquez de la Torre ML; Villà S; Perez de la Haza A; Calvo FA
    Lancet Oncol; 2015 Mar; 16(3):320-7. PubMed ID: 25702876
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Improving plan quality for prostate volumetric-modulated arc therapy.
    Wright K; Ferrari-Anderson J; Barry T; Bernard A; Brown E; Lehman M; Pryor D
    Med Dosim; 2017 Winter; 42(4):348-356. PubMed ID: 28784431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of planning margin on dosimetric quality in 131Cs permanent prostate brachytherapy.
    Li T; Fountain BL; Duffy EW
    Brachytherapy; 2010; 9(2):159-64. PubMed ID: 19853535
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review.
    Matzinger O; Poortmans P; Giraud JY; Maingon P; Budiharto T; van den Bergh AC; Davis JB; Musat E; Ataman F; Huyskens DP; Gulyban A; Bolla M;
    Radiother Oncol; 2009 Mar; 90(3):285-90. PubMed ID: 19038468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
    Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
    Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Technological advances in radiotherapy for the treatment of localised prostate cancer.
    Mangar SA; Huddart RA; Parker CC; Dearnaley DP; Khoo VS; Horwich A
    Eur J Cancer; 2005 Apr; 41(6):908-21. PubMed ID: 15808957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase I/II trial to evaluate three-dimensional conformal radiation therapy confined to the region of the lumpectomy cavity for Stage I/II breast carcinoma: initial report of feasibility and reproducibility of Radiation Therapy Oncology Group (RTOG) Study 0319.
    Vicini F; Winter K; Straube W; Wong J; Pass H; Rabinovitch R; Chafe S; Arthur D; Petersen I; McCormick B
    Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1531-7. PubMed ID: 16198508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy for Prostate Cancer: is it 'what you do' or 'the way that you do it'? A UK Perspective on Technique and Quality Assurance.
    Mason MD; Moore R; Jones G; Lewis G; Donovan JL; Neal DE; Hamdy FC; Lane JA; Staffurth JN;
    Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e92-e100. PubMed ID: 27425582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postoperative radiotherapy for prostate cancer: a comparison of four consensus guidelines and dosimetric evaluation of 3D-CRT versus tomotherapy IMRT.
    Malone S; Croke J; Roustan-Delatour N; Belanger E; Avruch L; Malone C; Morash C; Kayser C; Underhill K; Li Y; Malone K; Nyiri B; Spaans J
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):725-32. PubMed ID: 22444999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run.
    Kouloulias VE; Giraud JY; Davis BJ; Dusserre A; Zurlo A; Bolla M
    Radiother Oncol; 2004 Oct; 73(1):11-20. PubMed ID: 15465141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A multicentre year-long randomised controlled trial of exercise training targeting physical functioning in men with prostate cancer previously treated with androgen suppression and radiation from TROG 03.04 RADAR.
    Galvão DA; Spry N; Denham J; Taaffe DR; Cormie P; Joseph D; Lamb DS; Chambers SK; Newton RU
    Eur Urol; 2014 May; 65(5):856-64. PubMed ID: 24113319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lack of benefit for the addition of androgen deprivation therapy to dose-escalated radiotherapy in the treatment of intermediate- and high-risk prostate cancer.
    Krauss D; Kestin L; Ye H; Brabbins D; Ghilezan M; Gustafson G; Vicini F; Martinez A
    Int J Radiat Oncol Biol Phys; 2011 Jul; 80(4):1064-71. PubMed ID: 20584576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Coverage-based treatment planning to accommodate delineation uncertainties in prostate cancer treatment.
    Xu H; Gordon JJ; Siebers JV
    Med Phys; 2015 Sep; 42(9):5435-43. PubMed ID: 26328992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Vargas C; Martinez A; Kestin LL; Yan D; Grills I; Brabbins DS; Lockman DM; Liang J; Gustafson GS; Chen PY; Vicini FA; Wong JW
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1297-308. PubMed ID: 16029785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trial.
    Lamb DS; Denham JW; Joseph D; Matthews J; Atkinson C; Spry NA; Duchesne G; Ebert M; Steigler A; Delahunt B; D'Este C
    Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):385-91. PubMed ID: 20350786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensity-modulated radiation therapy for pancreatic and prostate cancer using pulsed low-dose rate delivery techniques.
    Li J; Lang J; Wang P; Kang S; Lin MH; Chen X; Chen F; Guo M; Chen L; Ma CM
    Med Dosim; 2014; 39(4):330-6. PubMed ID: 25087084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.